Latest News - Glaucoma

Wednesday, October 04, 2017 | Glaucoma, Medical Studies

Glaucoma Surgical Device Market to Grow More than 28 Percent by 2022

Market Scope forecasts that the glaucoma surgical device market will grow at a compound annual growth rate (CAGR) of 28.2 percent a year, totaling $1.8 billion by 2022. Glaucoma is the world’…

Read the full story

Wednesday, September 20, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa

Aerie Pharmaceuticals announced that a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA has been scheduled for October 13, 2017 to review the company’s new drug app…

Read the full story

Friday, September 08, 2017 | Glaucoma

How Well Can Glaucoma Patients Measure Their Own Intraocular Pressure?

Self-measurement of IOP by glaucoma patients is feasible and acceptable, but it remains to be seen whether it is sufficiently accurate to guide clinical management, according to an observational study…

Read the full story

Thursday, August 31, 2017 | Glaucoma, Alcon

Alcon Announces CyPass Micro-Stent’s Unique Procedure Code Becomes Effective, Paving the Way for Medicare Reimbursement

Alcon announced that the unique Current Procedural Terminology (CPT) code 0474T issued by the American Medical Association for the newly launched CyPass Micro-Stent is now effective. The CyPass Micro-…

Read the full story

Thursday, August 31, 2017 | Glaucoma, Medical Studies

Glaucoma Pharma Market to Grow to $5.3 Billion by 2022

Market Scope forecasts that the glaucoma pharmaceuticals market will grow at a compound annual growth rate (CAGR) of 3.4 percent a year, totaling $5.3 billion by 2022. Glaucoma is the second leadin…

Read the full story

Monday, July 24, 2017 | Clinical Trials, Glaucoma, BioLight

BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert

BioLight Life Sciences announced successful results from its glaucoma insert VS101 (Eye-D latanoprost insert) phase 1/2a clinical trial, which demonstrated its ability to lower IOP for a 12-week perio…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Roclatan Phase 3, 12-Month Topline Safety Results

Aerie Pharmaceuticals reported the successful 12-month safety results of the company’s “Mercury 1” phase 3 registration trial for its fixed-dose combination product candidate, Roclat…

Read the full story

Wednesday, June 21, 2017 | Clinical Trials, Glaucoma, Glaukos Corporation

Study: Combining Implantation of Glaukos iStent inject with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile

Glaukos announced that a study of 53 open-angle glaucoma subjects recently published in Clinical & Experimental Ophthalmology showed that the iStent inject Trabecular Micro-Bypass, combined with t…

Read the full story

Friday, June 16, 2017 | Awards, Glaucoma

New Grant Awarded to Assist Glaucoma Study

The National Eye Institute has awarded a $2.55 million R01 grant earmarked for exploring how glaucoma is associated with individual-specific biomechanics of the eye. University of Alabama at Birmingha…

Read the full story

Tuesday, June 06, 2017 | Glaucoma

Research and Markets Releases Report on Global MIGS Devices Market Opportunities and Forecast

Research and Markets has announced the addition of the "Global Micro-Invasive Glaucoma Surgery (MIGS) Devices Market (By Target, By Surgery, By End User, By Region, By Country): Opportunities and…

Read the full story

Friday, June 02, 2017 | Glaucoma

New Grant Will Fund Research of Biomechanical Markers in Glaucoma

Massimo A. Fazio, PhD, assistant professor in the University of Alabama at Birmingham Department of Ophthalmology, and Christopher A. Girkin, MD, have received a 4-year, $2.55 million R01 grant from t…

Read the full story

Monday, May 15, 2017 | Clinical Trials, Glaucoma

Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO

Isarna Therapeutics announced the presentation of the phase I safety and efficacy data for its lead candidate ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, in advanced-stage glau…

Read the full story

Monday, May 15, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa

Aerie Pharmaceuticals reported that it has received notification from the FDA that the agency has completed its initial 60-day review of the Rhopressa new drug application (NDA) and determined that th…

Read the full story

Thursday, April 13, 2017 | Acquisitions/Mergers, Glaucoma, Glaukos Corporation, MIGS

Glaukos Corporation Acquires IOP Sensor System from DOSE Medical

Glaukos announced that it has acquired the IOP sensor system assets and related liabilities from DOSE Medical Corporation for $5.5 million in cash, plus performance-based consideration of up to $9.5 m…

Read the full story

Thursday, April 13, 2017 | Glaucoma, MIGS

Sight Sciences Announces Health Canada Approval of the VISCO360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)

Sight Sciences announced that it has received Health Canada approval for the VISCO360 Viscosurgical System. The VISCO360 System is indicated in Canada for the microcatheterization and transluminal vis…

Read the full story
Load More